Israeli Startup Ayala Taking BMS Cancer Drug Into Phase II With $17m Financing

Ayala Pharma, which launched in late 2017, has raised $17m via a series A financing round to propel its lead precision cancer therapy into Phase II – an asset it licensed from Bristol-Myers Squibb.